Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are frequently encountered in ageing males. We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia. One hundred male patients older than 45 years were randomized to two groups containing 50 patients each; one group receiving alfuzosin 10 mg and the other group alfuzosin 10 mg combined with sildenafil 50 mg. International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), prostate volume and post‐void residual urine were evaluated. The mean age was 60.2 ± 17.8. Mean data of evaluated parameters in both groups at the end of 3rd month compared with baseline values are given respective order as; 5.1 (26.8%) and 5.8 (28.2%) points decreases in IPSS; 1.6 (41.1%) and 1.8 (45%) points decreases in QoL; and 3.4 (29.6%) and 3.4 (33%) points increases in Qmax. The outcomes of our study cannot be interpreted in such a way to report that alpha blocker‐PDE5 inhibitor combination has a better efficacy than alpha blocker treatment alone in patients with LUTS.

[1]  S. Permpongkosol,et al.  Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. , 2010, The journal of sexual medicine.

[2]  C. Roehrborn,et al.  Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment , 2010, BJU international.

[3]  A. Tuncel,et al.  Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction , 2010, World Journal of Urology.

[4]  M. Kuczyk,et al.  Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. , 2009, Urology.

[5]  A. Bechara,et al.  Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. , 2008, The journal of sexual medicine.

[6]  C. Stief,et al.  A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2008, European urology.

[7]  M. Elhilali,et al.  Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice , 2008, BJU international.

[8]  C. Roehrborn,et al.  Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia , 2007, International Journal of Impotence Research.

[9]  S. Madersbacher,et al.  Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment , 2007, International Journal of Impotence Research.

[10]  S. Kaplan,et al.  Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. , 2007, European urology.

[11]  K. McVary,et al.  Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. , 2007, The Journal of urology.

[12]  J. Mulhall,et al.  Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. , 2006, The journal of sexual medicine.

[13]  S. Kaplan,et al.  Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. , 2006, Urology.

[14]  K. McVary.  BPH: epidemiology and comorbidities. , 2006, The American journal of managed care.

[15]  C. Carson.  Combination of phosphodiesterase‐5 inhibitors and α‐blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? , 2006, BJU international.

[16]  T. Wilt,et al.  Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. , 2005, Urology.

[17]  R. Kloner,et al.  Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. , 2004, The Journal of urology.

[18]  J. Reynard.  Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? , 2004, Current opinion in urology.

[19]  M. Wyllie,et al.  Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003, BJU international.

[20]  E. Kulinskaya,et al.  Sildenafil influences lower urinary tract symptoms , 2002, BJU international.

[21]  U. Jonas,et al.  Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. , 2001, The Journal of urology.

[22]  C. Roehrborn,et al.  Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. , 2001, Urology.

[23]  J. Kozlowski,et al.  Intrinsic and extrinsic factors controlling benign prostatic growth , 1997, The Prostate.

[24]  J. Robinson.  The lower urinary tract. , 1982, British journal of clinical pharmacology.